Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma

Cancer Science

Volumn 100, Issue 12, 2009, Pages 2354-2360

  He, Li Ru ^a,b   Liu, Meng Zhong ^a,b   Li, Bin Kui ^a   Rao, Hui Lan ^a   Liao, Yi Ji ^a   Zhang, Lan Jun ^a   Guan, Xin Yuan ^a   Zeng, Yi Xin ^a   Xie, Dan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CLUSTERIN; FLUOROURACIL;

ADULT; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; EPITHELIUM; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; RADIOSENSITIVITY; SENSITIVITY ANALYSIS; STROMA CELL; SURVIVAL TIME; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CLUSTERIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 70649112059     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01349.x     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003, 349:2241-52.
3. Brenner B, Ilson DH, Minsky BD. Treatment of localized esophageal cancer. Semin Oncol 2004, 31:554-65.
4. Stahl M, Stuschke M, Lehmann N. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005, 23:2310-7.
5. Trougakos IP, Gonos ES. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 2002, 34:1430-48.
6. Shannan B, Seifert M, Leskov K. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ 2006, 13:12-9.
7. Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES. Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 2004, 64:1834-42.
8. Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 2004, 23:2298-304.
9. Moretti RM, Marelli MM, Mai S. Clusterin isoforms differentially affect growth and motility of prostate cells: possible implications in prostate tumorigenesis. Cancer Res 2007, 67:10325-33.
10. Trougakos IP, Djeu JY, Gonos ES, Boothman DA. Advances and challenges in basic and translational research on clusterin. Cancer Res 2009, 69:403-6.
11. Miyake H, Yamanaka K, Muramaki M, Kurahashi T, Gleave M, Hara I. Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. Oncol Rep 2005, 14:1371-5.
12. Kurahashi T, Muramaki M, Yamanaka K, Hara I, Miyake H. Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension. BJU Int 2005, 96:895-9.
13. Xie D, Lau SH, Sham JS. Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma. Cancer 2005, 103:277-83.
14. Watari H, Ohta Y, Hassan MK, Xiong Y, Tanaka S, Sakuragi N. Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy. Gynecol Oncol 2008, 108:527-32.
15. Kang YK, Hong SW, Lee H, Kim WH. Overexpression of clusterin in human hepatocellular carcinoma. Hum Pathol 2004, 35:1340-6.
16. Kruger S, Mahnken A, Kausch I, Feller AC. Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma. Urology 2006, 67:105-9.
17. Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M, Petito CK. Overexpression of clusterin in human breast carcinoma. Am J Pathol 2000, 157:393-9.
18. Xie D, Sham JS, Zeng WF. Oncogenic role of clusterin overexpression in multistage colorectal tumorigenesis and progression. World J Gastroenterol 2005, 11:3285-9.
19. Hara I, Miyake H, Gleave ME, Kamidono S. Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo. Jpn J Cancer Res 2001, 92:1220-4.
20. Miyake H, Hara I, Kamidono S, Gleave ME. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 2001, 7:4245-52.
21. Zellweger T, Chi K, Miyake H. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 2002, 8:3276-84.
22. July LV, Beraldi E, So A. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther 2004, 3:223-32.
23. Cao C, Shinohara ET, Li H. Clusterin as a therapeutic target for radiation sensitization in a lung cancer model. Int J Radiat Oncol Biol Phys 2005, 63:1228-36.
24. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-14.
25. Yamasaki F, Tokunaga O, Sugimori H. Apoptotic index in ovarian carcinoma: correlation with clinicopathologic factors and prognosis. Gynecol Oncol 1997, 66:439-48.
26. Sobin LH, Wittekind CL. TNM classification of malignant tumors 2002, eds, 6th edn, New York, John Wiley & Sons
27. Kevans D, Foley J, Tenniswood M. High clusterin expression correlates with a poor outcome in stage II colorectal cancers. Cancer Epidemiol Biomarkers Prev 2009, 18:393-9.
28. Andersen CL, Schepeler T, Thorsen K. Clusterin expression in normal mucosa and colorectal cancer. Mol Cell Proteomics 2007, 6:1039-48.
29. Pins MR, Fiadjoe JE, Korley F. Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report. Prostate Cancer Prostatic Dis 2004, 7:243-8.
30. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 2005, 7:909-15.
31. Park DC, Yeo SG, Wilson MR. Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer. Neoplasia 2008, 10:964-72.
32. Gleave M, Chi KN. Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers. Ann N Y Acad Sci 2005, 1058:1-15.
33. So A, Sinnemann S, Huntsman D, Fazli L, Gleave M. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol Cancer Ther 2005, 4:1837-49.
34. Hoeller C, Pratscher B, Thallinger C. Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol 2005, 124:1300-7.
35. Shin YJ, Kang SW, Jeong SY. Clusterin enhances proliferation of primary astrocytes through extracellular signal-regulated kinase activation. Neuroreport 2006, 17:1871-5.
36. Shim YJ, Shin YJ, Jeong SY. Epidermal growth factor receptor is involved in clusterin-induced astrocyte proliferation. Neuroreport 2009, 20:435-9.